Endpoints
SECONDARY
Endpoints are evaluated at 3-, 6-, and 12-month intervals from baseline. The primary endpoint is patient treatment satisfaction at month 12 as determined by the OAB-SAT-q satisfaction domain score. Key secondary endpoints supporting the primary endpoint include percent positive responses to individual satisfaction questions 1, 2, 3, and 11. Additional secondary endpoints include OAB-SAT-q scores for side effects, endorsement, convenience, and preference and reasons for treatment discontinuation. Exploratory endpoints include persistence and adherence. Safety will be assessed by types and incidence of AEs.